Two guys talking **it – A Gastroenterology and Hepatology podcast
Two guys talking **it - A Gastroenterology and Hepatology podcast
Podcast Description
“Two Guys Talking $#it” is a podcast where two Gastroenterologists break down complex topics into engaging, educational, and occasionally humorous conversations. From liver health to gut microbiota and everything in between, A/Professor Jonathan Segal and Dr James Haridy deliver insights, share the latest research, and discuss clinical pearls with the odd guest in tow.
Comments, suggestions, questions please contact us on twitter @2guystalkingit or leave a comment below..
Podcast Insights
Content Themes
The podcast covers a wide array of gastroenterology-related themes, including liver health, gut microbiota, coeliac disease, and disorders of gut-brain interaction. For instance, Episode #05 dives into the nuances of coeliac disease with A/Professor Jason Tye-Din, discussing diagnosis and emerging treatment strategies. Another episode features Professor Alex Ford, who examines irritable bowel syndrome (IBS) and its management, emphasizing the gut-brain connection.
“Two Guys Talking $#it” is a podcast where two Gastroenterologists break down complex topics into engaging, educational, and occasionally humorous conversations. From liver health to gut microbiota and everything in between, A/Professor Jonathan Segal and Dr James Haridy deliver insights, share the latest research, and discuss clinical pearls with the odd guest in tow.
Comments, suggestions, questions please contact us on twitter @2guystalkingit or leave a comment below..
We’re back for Season 2, and Jon and James kick things off with one of their favourite topics: Incretin mimetics. The gut is the biggest endocrine organ in the body, and the data in steatotic liver disease is now as good as anything we have in Hepatology for steatotic liver disease.
James and Jon cover the basic pharmacology, how to start and titrate these drugs in practice, what to tell patients about stopping them, the muscle loss question, endoscopy and anaesthesia, and a brief look at where the evidence is going across cardiovascular disease, kidney disease, sleep apnoea, IBD, and cancer. There is a lot going on with these drugs and this episode is the primer.
As always comments, questions, feedback and suggestions please send to:
X: @2guystalkingit
Email: [email protected]
Chapters
00:00 Intro: Season 2 is here
03:00 What are incretins? The gut as endocrine organ
06:30 Origin story: Gila Monster and the GLP-1 breakthrough 08:30 The drugs: semaglutide, tirzepatide, and what’s coming 10:00 How they actually work: satiety, the brain, and fat oxidation
12:00 Who to start: patient selection and caution groups
13:30 Lean MASH and Southeast Asian BMI thresholds
16:00 Exercise, muscle loss, and the resistance training argument
18:30 Side effects: nausea, constipation, lipase, mood
21:00 Endoscopy and anaesthesia: what to do
24:00 Titrating in practice: James’s approach
28:00 Stopping the drug: weight regain and the SURMOUNT data
33:00 Personalising treatment: who can stop, who shouldn’t 35:00 Eating disorders, body image, and screening
37:00 MASH data: ESSENCE and Synergy-NASH trials
39:30 Oral formulations: what’s available and caveats
40:30 Where bariatric surgery still fits
42:00 Broader indications: IBD, CVD, CKD, cancer
45:00 Global obesity trends and the public health message 47:00 Wrap-up
Papers discussed
Tirzepatide and fat oxidation, Cell Metabolism 2025
GLP-1 receptor agonists and 13 obesity-associated cancers
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.